# Amgen Inc. (AMGN) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/AMGN
## Company Profile
- Ticker: AMGN
- Exchange: NASDAQ
- Sector: 生物类似物,生物技术平台,肿瘤免疫治疗
- Location: Thousand Oaks, California
- Tags: Biologics, Biopharma, Pharmaceuticals, Novel Therapies, Immunotherapy, Gene Therapy, Rare Disease Gene Therapy, Large Molecule Drugs, Generics, Oncology, Rare Disease, Cardio-Metabolic
## Stock Data
- Close: 366.29 USD
- Market cap: 196124589688.86 USD
- Last updated: 2026-07-17
## Business Overview
Amgen is a large-cap biopharmaceutical company with a commercial base spanning oncology, inflammation, bone health, cardiovascular disease, and rare disease. Investors follow the stock for the mix of marketed products, late-stage pipeline optionality, and recurring regulatory or launch milestones.
## Why The Stock Is Moving

AMGN is trading like a steady large-cap biotech name rather than a sharp event-driven move. Its diversified revenue base, recurring approval cycle, and the market's wait for the next earnings or regulatory update keep the stock anchored.

## Geographic Base

Headquartered in Thousand Oaks, California and listed on NASDAQ, Amgen is followed within the large-cap biotechnology universe for its exposure to diversified therapeutics and global commercial execution.

## Business Model

Amgen follows a hybrid model where commercial cash flow supports research, development, and business development. Launch execution, regulatory events, and portfolio refresh matter more than pure clinical-stage binary risk.

## Landscape Position

Compared with smaller clinical-stage peers, Amgen sits toward the more mature end of the biotech landscape, where cash generation, portfolio breadth, and execution consistency matter alongside catalysts.

## Future Catalysts

- Over the next three months, the stock is likely to react to earnings, conference commentary, and regulatory follow-through tied to the pipeline or existing labels.
- The next earnings call should be the first major checkpoint because it can update revenue trends, margin signals, and management's view on capital allocation and pipeline priorities.
- Conference season also matters. Scientific and investor meetings can surface new data points, launch details, and commentary on oncology and cardiometabolic programs before the wider market fully reprices them.
- Regulatory milestones and label updates remain the main optionality layer. Any FDA decision or supplemental filing can quickly change the narrative around the newest approved or late-stage assets.

## Recent News
- 2026-07-20 10:59 EST — [Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA](https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-build-the-most-powerful-ai-factory-in-life-sciences-with-eb3e7bda) — Source: BMYBristol-Myers Squibb Company
- 2026-07-20 07:00 EST — [European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds](https://biopharmsignal.com/news/GSK/european-medicines-agency-accepts-submission-to-update-bexsero-label-for-1-dose--8906d096) — Source: GSK plc
- 2026-07-17 09:00 EST — [GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)](https://biopharmsignal.com/news/GSK/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials-for-camlipixant-in--0e112206) — Source: GSK plc
- 2026-07-16 12:31 EST — [Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia](https://biopharmsignal.com/news/MRK/merck-s-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibit-1b899588) — Source: Merck
- 2026-07-16 12:00 EST — [Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ALNY/alnylam-to-webcast-conference-call-discussing-second-quarter-2026-financial-resu-458d7635) — Source: Alnylam Pharmaceuticals, Inc.